The respiratory syncytial virus (RSV) vaccine (Abrysvo) was linked with fewer hospitalizations and emergency department (ED) ...

Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or ...

by rapidly identifying RSV infection, health professionals can implement appropriate infection control measures while limiting unnecessary testing and antibiotic treatment. Diagnosis is impossible ...

Future Microbiol. 2013;8(4):435-444.

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval ...

Starting Oct. 28, the rest of the general public are recommended to also get vaccinated, says region's health unit ...

The RSV vaccine Abrysvo was highly effective against hospital and ED encounters in a large cohort of older adults with comorbidities and immunocompromising conditions.

In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy ...

oxygen saturation test, or computed tomography (CT) scan. Blood and urinary cultures may also be performed (bronchiolitis related to RSV can occur with a urinary tract infection in newborns). It can ...

What is this silent virus that endangers Filipino Seniors with comorbidities? Respiratory Syncytial Virus (RSV) is not just another cold or flu—it is potentially life- threatening for ...

A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the ...

Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...